Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026)
Ardelyx's (ARDX) quarterly Other Non-Current Liabilities came in at $25.9 million in Q1 2026, down 2.48% YoY from $26.5 million in Q1 2025, and little changed on a QoQ basis from $25.9 million in Q4 2025.
Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 13 years of Other Non-Current Liabilities data on file, last reported at $25.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 2.48% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (down 2.48% YoY) and the FY2025 annual result came in at $25.9 million, up 1.37% from the prior year.
- Other Non-Current Liabilities held at $25.9 million in Q1 2026, from $25.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $28.6 million in Q3 2025 to a low of $170000.0 in Q3 2023.
- A 5-year average of $19.2 million and a median of $22.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 98.37% — and 2024, when it surged 14236.47%.
- Tracing ARDX's Other Non-Current Liabilities over 5 years: stood at $11.3 million in 2022, then surged by 79.31% to $20.2 million in 2023, then increased by 26.5% to $25.5 million in 2024, then increased by 1.37% to $25.9 million in 2025, then declined by 0.05% to $25.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $25.9 million (Q1 2026), $25.9 million (Q4 2025), and $28.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.32 Mn |
| Mar 31, 2026 | 25.86 Mn |
| Dec 31, 2025 | 25.88 Mn |
| Sep 30, 2025 | 28.63 Mn |
| Jun 30, 2025 | 27.76 Mn |
| Mar 31, 2025 | 26.52 Mn |
| Dec 31, 2024 | 25.53 Mn |
| Sep 30, 2024 | 24.37 Mn |
| Jun 30, 2024 | 23.10 Mn |
| Mar 31, 2024 | 21.88 Mn |
| Dec 31, 2023 | 20.18 Mn |
| Sep 30, 2023 | 170,000.00 |
| Jun 30, 2023 | 13.19 Mn |
| Mar 31, 2023 | 12.22 Mn |
| Dec 31, 2022 | 11.25 Mn |
| Sep 30, 2022 | 10.42 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Dec 31, 2020 | 1.38 Mn |
| Sep 30, 2020 | 1.26 Mn |
| Jun 30, 2020 | 1.12 Mn |